Duality Biotherapeutics, Inc., incorporated in 2019, is a clinical-stage biopharmaceutical company focused on the discovery and development of antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company operates four proprietary ADC technology platforms: DITAC, DIBAC, DIMAC, and DUPAC. Its pipeline consists of internally discovered ADC candidates, including clinical-stage assets, next-generation bispecific ADCs, and autoimmune-focused therapies. Duality Biotherapeutics conducts global multi-center clinical trials and has established licensing and collaboration agreements with global pharmaceutical partners, including a global collaboration with Genentech, a subsidiary of Roche, to develop next-generation ADCs based on the DUPAC payload platform. The company’s principal customers are partners under these license and collaboration agreements.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage dualitybiologics.com
Sector Healthcare IR page dualitybiologics.com/investor
Tags
antibody-drug conjugates, oncology, autoimmune diseases, bispecific antibodies, clinical-stage, payload technology, pancreatic cancer, DITAC, DIBAC, DIMAC, DUPAC, DB-1317, Genentech, Roche
Press page dualitybiologics.com/news/index.html

Metrics

Valuation  
Market cap HK$ 8.38B
Market cap (USD) $ 1.068B
P/E -4.95
PEG —
P/BV 3.51
P/S 8.46
P/OCF -8.70
P/FCF —
Dividend yield —
Turnover / mcap 0.53%
Returns  
ROE -106.9%
ROI -101.1%
ROIC -14.2%
Profit margin -140.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity 16.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 1.852B 1.941B
Net profit -2.595B -1.05B

Figure FY 2025 FY 2024
Share price 317.29 —
P/OCF 106.24 —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Duality Biotherapeutics, Inc. (ticker 9606), listed in Hong Kong.